Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With PD Undergoing Deep Brain Stimulation
A Pilot Study to Evaluate the Safety and Feasibility of Implanting Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With Parkinson's Disease Undergoing Deep Brain Stimulation Surgery and Treatment
Status: Enrolling
Updated:  3/8/2016
University of Kentucky Medical Center
mi
from
Lexington, KY
Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With PD Undergoing Deep Brain Stimulation
A Pilot Study to Evaluate the Safety and Feasibility of Implanting Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With Parkinson's Disease Undergoing Deep Brain Stimulation Surgery and Treatment
Status: Enrolling
Updated: 3/8/2016
University of Kentucky Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With PD Undergoing Deep Brain Stimulation
A Pilot Study to Evaluate the Safety and Feasibility of Implanting Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With Parkinson's Disease Undergoing Deep Brain Stimulation Surgery and Treatment
Status: Enrolling
Updated:  3/8/2016
University of Kentucky Medical Center
mi
from
Lexington, KY
Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With PD Undergoing Deep Brain Stimulation
A Pilot Study to Evaluate the Safety and Feasibility of Implanting Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With Parkinson's Disease Undergoing Deep Brain Stimulation Surgery and Treatment
Status: Enrolling
Updated: 3/8/2016
University of Kentucky Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Biomarker Discovery in Parkinson's Disease
Proteomics, Metabolomics, Lipidomics and Genetic Analysis for Biomarker DISCOVERY in Parkinson's Disease
Status: Enrolling
Updated:  3/10/2016
Parkinson's Institute and Clinical Center
mi
from
Sunnyvale, CA
Biomarker Discovery in Parkinson's Disease
Proteomics, Metabolomics, Lipidomics and Genetic Analysis for Biomarker DISCOVERY in Parkinson's Disease
Status: Enrolling
Updated: 3/10/2016
Parkinson's Institute and Clinical Center
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
Deep Brain Stimulation in Patients With Parkinson's Disease
The Effect of Deep Brain Stimulation on Movement-Related Cortical Potentials in Patients With Parkinson's Disease
Status: Enrolling
Updated:  3/17/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Deep Brain Stimulation in Patients With Parkinson's Disease
The Effect of Deep Brain Stimulation on Movement-Related Cortical Potentials in Patients With Parkinson's Disease
Status: Enrolling
Updated: 3/17/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis Investigative Site
mi
from
Englewood, CO
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis Investigative Site
mi
from
Englewood, CO
Click here to add this to my saved trials
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis Investigative Site
mi
from
Kansas City, KA
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis Investigative Site
mi
from
Kansas City, KA
Click here to add this to my saved trials
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis Investigator Site
mi
from
Milwaukee, WI
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis Investigator Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis investigative site
mi
from
Innsbruck,
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis investigative site
mi
from
Innsbruck,
Click here to add this to my saved trials
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis Investigative Site
mi
from
Sunnyvale, CA
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis Investigative Site
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis Investigative Site
mi
from
Englewood, CO
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis Investigative Site
mi
from
Englewood, CO
Click here to add this to my saved trials
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis Investigative Site
mi
from
Indianapolis, IN
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis Investigative Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  3/22/2016
Novartis Investigative Site
mi
from
Heidelberg,
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 3/22/2016
Novartis Investigative Site
mi
from
Heidelberg,
Click here to add this to my saved trials
Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease
Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease
Status: Enrolling
Updated:  3/23/2016
University of Miami
mi
from
Miami, FL
Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease
Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease
Status: Enrolling
Updated: 3/23/2016
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated:  3/28/2016
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated: 3/28/2016
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated:  3/28/2016
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated: 3/28/2016
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Click here to add this to my saved trials
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated:  3/28/2016
Parkinson's Disease and Movement Disorders Center of Boca Raton
mi
from
Boca Raton, FL
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated: 3/28/2016
Parkinson's Disease and Movement Disorders Center of Boca Raton
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated:  3/28/2016
MD Clinical
mi
from
Hallandale Beach, FL
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated: 3/28/2016
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated:  3/28/2016
Compass Research LLC
mi
from
Orlando, FL
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated: 3/28/2016
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated:  3/28/2016
QUEST Research Institute
mi
from
Bingham Farms, MI
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated: 3/28/2016
QUEST Research Institute
mi
from
Bingham Farms, MI
Click here to add this to my saved trials
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated:  3/28/2016
Oregon Health and Science University, Department of Neurology
mi
from
Portland, OR
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated: 3/28/2016
Oregon Health and Science University, Department of Neurology
mi
from
Portland, OR
Click here to add this to my saved trials
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated:  3/28/2016
Baylor College of Medicine
mi
from
Houston, TX
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Status: Enrolling
Updated: 3/28/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Natural History of Levodopa-Induced Dyskinesia (LID)
Determining the Natural History of Levodopa-Induced Dyskinesia (LID)
Status: Enrolling
Updated:  4/4/2016
Oregon Health and Science University
mi
from
Portland, OR
Natural History of Levodopa-Induced Dyskinesia (LID)
Determining the Natural History of Levodopa-Induced Dyskinesia (LID)
Status: Enrolling
Updated: 4/4/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Orange Coast Memorial Medical Center
mi
from
Fountain Valley, CA
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Orange Coast Memorial Medical Center
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
The Parkinson's & Movement Disorder Institute
mi
from
Fountain Valley, CA
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
The Parkinson's & Movement Disorder Institute
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Rocky Mountain Movement Disorders Center
mi
from
Englewood, CO
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Rocky Mountain Movement Disorders Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Davita Clinical Research Center
mi
from
Lakewood, CO
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Davita Clinical Research Center
mi
from
Lakewood, CO
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
MD Clinical
mi
from
Hallandale Beach, FL
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Compass Research LLC
mi
from
Orlando, FL
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Massachusetts General Hospital -- FOR DRUG SHIPMENT ONLY
mi
from
Boston, MA
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Massachusetts General Hospital -- FOR DRUG SHIPMENT ONLY
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Massachusetts General Hospital
mi
from
Boston, MA
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
QUEST Research Institute
mi
from
Farmington Hills, MI
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
QUEST Research Institute
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
PRA International
mi
from
Marlton, NJ
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
PRA International
mi
from
Marlton, NJ
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Carolina Phase I Research, LLC
mi
from
Raleigh, NC
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Carolina Phase I Research, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Neurology Consultants of Dallas, PA
mi
from
Dallas, TX
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Neurology Consultants of Dallas, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated:  4/4/2016
Walnut Hill Medical Center
mi
from
Dallas, TX
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations
Status: Enrolling
Updated: 4/4/2016
Walnut Hill Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site
mi
from
Birmingham, AL
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 10276
mi
from
Tucson, AZ
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 10276
mi
from
Tucson, AZ
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 004
mi
from
Irvine, CA
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 004
mi
from
Irvine, CA
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 04
mi
from
La Jolla, CA
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 04
mi
from
La Jolla, CA
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 176
mi
from
Loma Linda, CA
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 176
mi
from
Loma Linda, CA
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site
mi
from
Los Angeles, CA
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 02
mi
from
Sunnyvale, CA
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 02
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 035
mi
from
Danbury, CT
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 035
mi
from
Danbury, CT
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 7016
mi
from
Farmington, CT
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 7016
mi
from
Farmington, CT
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 30
mi
from
Boca Raton, FL
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 30
mi
from
Boca Raton, FL
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 12299
mi
from
Gainesville, FL
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 12299
mi
from
Gainesville, FL
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 1345
mi
from
Miami, FL
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 1345
mi
from
Miami, FL
Click here to add this to my saved trials